

JETRO delegation company video pitch list

[SEEDSUPPLY INC.](#)



Naoki Tarui
CEO
naoki.tarui@seedsupply.co.jp

SEEDSUPPLY INC. is a contract research organization in Japan and we have the technology to identify seed compounds that lead to first in class drug.

- ◆Service1_Binding compounds screening
- ◆Service2_Binding proteins identification

[Tsubota Laboratory, Inc.](#)



Ryo Konno
Business development manager
konno@tsubota-lab.com

Tsubota Laboratory, Inc. is a privately held clinical development stage company focusing on out-licensing of novel solutions for ophthalmology (myopia prevention) and central nerve system (Parkinson's disease, depression, mild cognitive impairment).

Neurological disease, Ocular disease, Central nervous system development disorder, etc.

[Braizon Therapeutics, Inc.](#)



Philip Davy
Director of Business Development
fwanibuchi@braizon.com

We have developed a drug delivery technology for crossing the Blood Brain Barrier via Glucose Transporter using a polymer nano-particle carrier

Psychiatric disorder, Central nervous system disease, Central nervous system infection, etc.

[K.K. CYBO](#)



Nao Nitta
President
nitta@cybo.co.jp

CYBO develop advanced innovative devices and AI software to inspect cells one-by-one to find target cells at unprecedented speed.

Hematological disease, Immune disorder, Infectious disease, etc.

[PuREC Co., Ltd.](#)



Hide Takahashi
COO & CFO
htakahashi@purec.jp

PuREC is a biotechnology company with its proprietary technology to obtain "REC", ultra-high-purity MSC derived from human bone marrow to help treat various intractable diseases.

Hyperphosphatasia

[Hamamatsu Pharma Research, Inc.](#)



Yoko Drexler
Business development lead
yj-matsumoto@hpharma.jp

Nonhuman primate disease model pharmacological evaluation and noninvasive in vivo imaging.

Inflammatory bowel disease, Thrombosis, Cerebrovascular reperfusion injury, etc.

REPROCELL



Daisuke Usui
Chief Operating Officer
yukiko.onishi@reprocell.com

The REPROCELL Group is dedicated to providing researchers with single source bench-to bedside solutions for the advancement of stem cell and human tissue research in drug discovery and regenerative medicine.

Cardiovascular disease, Dermatological disease, Gastrointestinal disease, etc.

MabGenesis Inc.



Yuichiro Shibazaki
Chief Business Officer
shibazaki_yuichiro@mabgenesis.com

Expand druggable space by providing first-in-class and best-in-class therapeutic monoclonal antibodies against hard-to-drug targets in human and animal fields.

SUSMED, Inc



Rei Okamoto
Alliance Group Leader
rei.okamoto@susmed.co.jp

SUSMED is a Digital Medicine-relevant startup founded in 2015 by Taro Ueno who is CEO of SUSMED as well as M.D and psychiatrist. Our product portfolio is composed of three products including a treatment app and platforms.

Neurological disease, Sleep disorder, Insomnia, Sleep maintenance insomnia, etc.

Oligogen, Inc.



Tsuneo Kido
President & CEO
mnakashima@oligogen.jp

Oligogen, Inc. is a bio-venture company specializing in the research and development of cell therapy products using a new type of human neural stem cell, "OligoGenie".

C4U Corporation



Akimitsu Hirai
CEO and President
hirai@crispr4u.com

Our technology, CRISPR-Cas3 has significant features, such as: High specificity, wide deletion and no off-target. In addition, we could provide FTO in terms of patent protection world wide.

United Immunity, Co., Ltd.



Akihiko Watanabe
CBO
akihiko.watanabe@unitedimmunity.co.jp

A Japanese startup developing novel combination immunotherapies effective even for immune checkpoint inhibition-resistant tumors.

Neoplasm, Cancer, Advanced solid tumor, Leukemia, Lymphoma, etc.

Momotaro-Gene Inc.



Hitoshi Shiomi
CEO
shiomi@mt-gene.com

Phase I/IIa in Japan and US for malignant mesothelioma and prostate cancer. We have a Japanese partner, Kyorin Pharmaceuticals and a Chinese partner, EPS Co. Ltd. We are seeking for US/EU partner for our leading product, Ad-SGE-REIC.

Neoplasm

[Link to Bio Digital JETRO page](#)